EQS-News: APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
Error message
- Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, continues to keep up the pace for the ongoing expansion of its portfolio to at least 20 Single Pills by 2026 with the in-licensing of two new Single Pills.
EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals The issuer is solely responsible for the content of this announcement. APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
The two new in-licensing products are Single Pills that are used to treat hypertension (high blood pressure). APONTIS PHARMA is relying on its proven approach of combining several active ingredients in a Single Pill. The two new Single Pills open up additional targeted treatment options for the growing number of hypertension patients in Germany. APONTIS PHARMA anticipates total potential peak sales of EUR 4.0 million. The advantage of combining several active ingredients in a Single Pill is quite obvious: The reduction to one drug increases patients’ adherence to take the medication for a more efficient therapy. The success of Single Pill therapy is confirmed by the retrospective START study conducted in 2019. It concludes that medications are taken more reliably when the daily dosage form is limited to one pill. The efficiency of Single Pills is also confirmed by the prospective SECURE study funded by the European Union. Its outstandingly positive results were presented at the end of August 2022 at the European Cardiology Congress in Barcelona and published simultaneously in the renowned New England Journal of Medicine. APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe’s leading pharmaceutical and chemical regions. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. Investor Relations CROSS ALLIANCE communication GmbH
29.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | APONTIS PHARMA AG |
Alfred-Nobel-Str. 10 | |
40789 Monheim | |
Germany | |
E-mail: | [email protected] |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Frankfurt (Scale) |
EQS News ID: | 1497417 |
End of News | EQS News Service |
|
1497417 29.11.2022 CET/CEST